



Erratum

Erratum. Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin. Diabetes Care 2015;38:384–393

DOI: 10.2337/dc15-er06

*Ralph A. DeFronzo, Andrew Lewin,
Sanjay Patel, Dacheng Liu, Renee Kaste,
Hans J. Woerle, and Uli C. Broedl*

In the print version of the article cited above, mean (SD) body weight for empagliflozin 10 mg should be 86.1 kg (18.2) [rather than 85.7 kg (18.4)] in Table 1. In addition, in Supplementary Table 3, for LDL-cholesterol, the adjusted mean (SE) change from baseline in difference vs. empagliflozin 10 mg [rather than difference vs. empagliflozin 25 mg] for empagliflozin 10 mg/linagliptin 5 mg should be -0.1 (0.1) mmol/L; $P = 0.555$. The online version reflects these changes.